What You Should Know
- The Launch: The Advanced Research Projects Agency for Health (ARPA-H) has announced STOMP (Systematic Targeting Of MicroPlastics), a massive $144 million nationwide program.
- The Ultimate Goal: STOMP aims to develop tools that are fast, affordable, and broadly available, specifically protecting vulnerable populations like pregnant women, children, and highly exposed workers from long-term disease.
Fixing the Data Layer First
While microplastics and nanoplastics (MNPs) have been detected in human lungs, arterial plaques, and brains, the medical community currently lacks precise, standardized tools to measure the burden or fully understand the biological harm of specific plastic types.
Before ARPA-H can fund the removal of these plastics, it has to fix the fundamental data problem. Currently, microplastic measurement techniques produce wildly inconsistent results from lab to lab.
Phase One of STOMP is entirely focused on measurement and mechanism. The goal is to develop gold-standard clinical tests that can accurately quantify a patient’s microplastic burden at scale. Crucially, ARPA-H is bringing in the CDC as an independent validator to ensure the new methods are universally trusted.
This phase will also produce a “risk stratification mechanism.” Not all plastics are created equal; some polymers may pass through the body harmlessly, while others may cross cellular barriers and trigger severe inflammation. By ranking plastics by biological harm, STOMP will finally give the biotech industry a prioritized hit list.
“Microplastics are in every organ we look at—in ourselves and in our children. But we don’t know which ones are harmful or how to remove them,” said Alicia Jackson, Ph.D., ARPA-H Director. “Nobody wants unknown particles accumulating in their body. The field is working in the dark. STOMP is turning on the lights.”
Phase Two (Removal)
Utilizing the data from Phase One, researchers will draw on pharmaceutical biology and bioremediation science to design interventions that safely and effectively remove accumulated microplastics from human organs.
The agency explicitly states that these removal approaches will draw on “pharmaceutical biology and bioremediation science, run in reverse.” This is a staggering technological leap. Bioremediation is typically used to clean up oil spills or contaminated soil using microorganisms. Adapting those principles to safely bind, neutralize, or extract synthetic nanoplastics from living human brain or lung tissue represents a genuine medical moonshot.
ARPA-H Program Manager Shannon Greene, Ph.D. noted, “It’s physically impossible for us to completely divorce our lives from plastics. They are in everything we touch—our clothes, the materials from which we get our food and water. We need to understand how microplastics are distributed throughout the body and what harm they are causing before we can take the next leap forward to ultimately remove them and improve human health.”
